The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Open accessAbstract
Interactions between histone deacetylase inhibitors (HDACIs) and decitabine were investigated in models of diffuse large B-cell lymphoma (DLBCL). A number of cell lines representing both germinal center B-like and activated B-cell like DLBCL, patient-derived tumor cells and a murine xenograft model were used to study the effects of HDACIs and decitabine in this system. All explored HDACIs in combination with decitabine produced a synergistic effect in growth inhibition and induction of apoptosis in DLBCL cells. This effect was time dependent, mediated via caspase-3 activation, and resulted in increased levels of acetylated histones. Synergy in inducing apoptosis was confirmed in patient-derived primary tumor cells treated with panobinostat and decitabine. Xenografting experiments confirmed the in vitro activity and tolerability of the combination. We analyzed the molecular basis for this synergistic effect by evaluating gene-expression and methylation patterns using microarrays, with validation by bisulfite sequencing. These analyses revealed differentially expressed genes and networks identified by each of the single treatment conditions and by the combination therapy to be unique with few overlapping genes. Among the genes uniquely altered by the combination of panobinostat and decitabine were VHL, TCEB1, WT1, and DIRAS3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor
Prokhortchouk, A., Hendrich, B., Jørgensen, H., Ruzov, A., Wilm, M., Georgiev, G., Bird, A., & Prokhortchouk, E. (2001) · Genes & Development · doi:10.1101/gad.198501 · Cited by 533
Cited by
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 287
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Metadata
- Authors
- Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V. E., Bhagat, G., Ulahannan, N., Leshchenko, V. V., Temkin, A. M., Parekh, S., Tycko, B., & O'Connor, O. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-11-17
- Volume
- 118
- Issue
- 20
- Pages
- 5506-5516
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1988466148
- Cited by
- 158
- References
- 3
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. https://app.cochat.ai/papers/10.1182/blood-2011-02-336891
- The paper
- Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V. E., Bhagat, G., Ulahannan, N., Leshchenko, V. V., Temkin, A. M., Parekh, S., Tycko, B., & O'Connor, O. A. (2011). HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. https://doi.org/10.1182/blood-2011-02-336891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.